Ken Griffin Cure Vac N.V. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cure Vac N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,200 shares of CVAC stock, worth $63,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,200

Previous 21,200 9.43%

Holding current value

$63,800

Previous $72,000 5.56%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.74 - $3.79 $2.06 Million - $2.85 Million	751,007 Added 288.26%	1,011,537 $2.97 Million
Q2 2024 Aug 14, 2024	SELL	$2.31 - $4.99 $1.66 Million - $3.59 Million	-719,974 Reduced 73.43%	260,530 $885,000
Q1 2024 May 15, 2024	BUY	$2.94 - $4.34 $229,337 - $338,546	78,006 Added 8.64%	980,504 $2.97 Million
Q4 2023 Feb 14, 2024	SELL	$3.96 - $6.41 $8.6 Million - $13.9 Million	-2,171,495 Reduced 70.64%	902,498 $3.8 Million
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $4.68 Million - $7.76 Million	720,193 Added 30.6%	3,073,993 $21 Million
Q2 2023 Aug 14, 2023	SELL	$6.69 - $12.25 $3.89 Million - $7.12 Million	-581,503 Reduced 19.81%	2,353,800 $24.5 Million
Q1 2023 May 15, 2023	BUY	$6.38 - $12.5 $6.09 Million - $11.9 Million	954,433 Added 48.18%	2,935,303 $20.5 Million
Q4 2022 Feb 14, 2023	BUY	$5.75 - $8.5 $11 Million - $16.2 Million	1,909,554 Added 2677.6%	1,980,870 $11.9 Million
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $396,544 - $807,933	-53,014 Reduced 42.64%	71,316 $562,000
Q2 2022 Aug 15, 2022	SELL	$13.18 - $19.41 $2.27 Million - $3.34 Million	-172,270 Reduced 58.08%	124,330 $1.69 Million
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $4.12 Million - $9.85 Million	279,368 Added 1621.22%	296,600 $5.82 Million
Q4 2021 Feb 14, 2022	SELL	$33.72 - $48.22 $1.45 Million - $2.07 Million	-42,899 Reduced 71.34%	17,232 $591,000
Q3 2021 Nov 15, 2021	BUY	$49.26 - $74.5 $2.54 Million - $3.84 Million	51,585 Added 603.62%	60,131 $3.29 Million
Q2 2021 Aug 16, 2021	BUY	$56.91 - $127.53 $320,061 - $717,228	5,624 Added 192.47%	8,546 $627,000
Q1 2021 May 17, 2021	SELL	$79.79 - $126.29 $1.14 Million - $1.81 Million	-14,332 Reduced 83.06%	2,922 $267,000
Q4 2020 Feb 16, 2021	BUY	$46.76 - $136.27 $806,797 - $2.35 Million	17,254 New	17,254 $1.4 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $516M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account